Multiple myeloma management: What comes after lenalidomide-based therapy?
Canadian Hematology Today · 2022
DOI: 10.58931/cht.2022.1213 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Hematology Today, 2022. Verfasst von Martha Louzada. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Over the past two decades a myriad of new combination strategies and therapeutic agents for the treatment of multiple myeloma (MM) have been developed. Novel drug classes such as proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies have demonstrated very promising efficacy outcomes related to survival endpoints and improvements in quality of life for myeloma patients.
Zitieren
APA
Louzada, M. (2022). Multiple myeloma management: What comes after lenalidomide-based therapy?. Canadian Hematology Today. https://doi.org/10.58931/cht.2022.1213
Vancouver
Louzada M. Multiple myeloma management: What comes after lenalidomide-based therapy?. Canadian Hematology Today. 2022. doi:10.58931/cht.2022.1213
BibTeX
@article{Louzada2022,
author = {Louzada, Martha},
title = {Multiple myeloma management: What comes after lenalidomide-based therapy?},
journal = {Canadian Hematology Today},
year = {2022},
doi = {10.58931/cht.2022.1213}
}
EUVIMED